Instil Bio, Inc. Research and Development Expense
Instil Bio, Inc. (TIL) reported Research and Development Expense of $2.92 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-08-13
- Instil Bio, Inc. research and development expense for the quarter ending 2024-06-30 was $2.92M, a 65.47% decline year-over-year.
- Instil Bio, Inc. research and development expense for the quarter ending 2024-03-31 was $7.26M, a 64.90% decline year-over-year.
- Instil Bio, Inc. research and development expense for the quarter ending 2023-12-31 was $1.98M, a 90.43% decline year-over-year.
- Instil Bio, Inc. research and development expense for the quarter ending 2023-09-30 was $8.49M, a 78.59% decline year-over-year.
- Instil Bio, Inc. research and development expense for fiscal 2023 was $39.60M, a 71.92% decline from fiscal 2022.
- Instil Bio, Inc. research and development expense for fiscal 2022 was $141.06M, a 31.52% increase from fiscal 2021.
- Instil Bio, Inc. research and development expense for fiscal 2021 was $107.25M, a 452.87% increase from fiscal 2020.
- Instil Bio, Inc. research and development expense for fiscal 2020 was $19.40M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $2.92M 10-Q · filed 2024-08-13 | $10.18M 10-Q · filed 2024-08-13 | $12.16M derived: sum of 3 quarters · filed 2024-08-13 | $20.65M derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | $7.26M 10-Q · filed 2024-05-10 | $9.24M derived: sum of 2 quarters · filed 2024-05-10 | $17.73M derived: sum of 3 quarters · filed 2024-05-10 | $26.19M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $10.47M derived: sum of 2 quarters · filed 2024-03-21 | $18.93M derived: sum of 3 quarters · filed 2024-08-13 | $39.60M 10-K · filed 2024-03-21 |
| 2023-09-30 | $8.49M 10-Q · filed 2023-11-13 | $16.95M derived: sum of 2 quarters · filed 2024-08-13 | $37.62M 10-Q · filed 2023-11-13 | $58.34M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-06-30 | $8.46M 10-Q · filed 2024-08-13 | $29.13M 10-Q · filed 2024-08-13 | $49.85M derived: sum of 3 quarters · filed 2024-08-13 | $89.51M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $20.67M 10-Q · filed 2024-05-10 | $41.39M derived: sum of 2 quarters · filed 2024-05-10 | $81.05M derived: sum of 3 quarters · filed 2024-05-10 | $122.55M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $20.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $60.38M derived: sum of 2 quarters · filed 2024-03-21 | $101.88M derived: sum of 3 quarters · filed 2024-03-21 | $141.06M 10-K · filed 2024-03-21 |
| 2022-09-30 | $39.66M 10-Q · filed 2023-11-13 | $81.16M derived: sum of 2 quarters · filed 2023-11-13 | $120.33M 10-Q · filed 2023-11-13 | $162.91M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $41.50M 10-Q · filed 2023-08-14 | $80.67M 10-Q · filed 2023-08-14 | $123.25M derived: sum of 3 quarters · filed 2023-08-14 | $152.31M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $39.17M 10-Q · filed 2023-05-11 | $81.75M derived: sum of 2 quarters · filed 2023-05-11 | $110.81M derived: sum of 3 quarters · filed 2023-05-11 | $132.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $42.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $71.64M derived: sum of 2 quarters · filed 2023-03-31 | $92.83M derived: sum of 3 quarters · filed 2023-03-31 | $107.25M 10-K · filed 2023-03-31 |
| 2021-09-30 | $29.06M 10-Q · filed 2022-11-14 | $50.25M derived: sum of 2 quarters · filed 2022-11-14 | $64.67M 10-Q · filed 2022-11-14 | $74.92M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $21.19M 10-Q · filed 2022-08-12 | $35.61M 10-Q · filed 2022-08-12 | $45.86M derived: sum of 3 quarters · filed 2022-08-12 | $50.77M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $14.42M 10-Q · filed 2022-05-16 | $24.67M derived: sum of 2 quarters · filed 2022-05-16 | $29.58M derived: sum of 3 quarters · filed 2022-05-16 | $31.82M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $10.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $15.15M derived: sum of 2 quarters · filed 2022-03-07 | $17.39M derived: sum of 3 quarters · filed 2022-03-07 | $19.40M 10-K · filed 2022-03-07 |
| 2020-09-30 | $4.91M 10-Q · filed 2021-11-15 | $7.14M derived: sum of 2 quarters · filed 2021-11-15 | $9.15M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.24M 10-Q · filed 2021-08-12 | $4.25M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $2.01M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |